HRMY Stock Analysis: Buy, Sell, or Hold?
HRMY - Harmony Biosciences Holdings, Inc. Common Stock
$38.14
0.02 (0.05%)
â˛
5d:
-2.21%
30d:
+12.94%
90d:
+26.75%
WAIT
LOW Confidence
Analysis Updated: Aug 17, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When HRMY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: HRMY is fairly priced but lacks strong directional signals. At -1.1% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: HRMY is fairly priced but lacks strong directional signals. At -1.1% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$76.82
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$47.70
20.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 5.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HRMY is currently trading at $38.14, which is considered slightly high relative to its 30-day fair value range of $34.78 to $38.47. The stock's valuation (Forward PE: 5.7) is in line with its historical norms (5.9). Remarkably, the market is currently pricing in an annual earnings decline of 1.1% over the next few years. This pessimistic expectation contrasts with the company's recent 88.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, HRMY is in a strong uptrend. Immediate support is located at $36.80, while resistance sits at $40.15.
Market Sentiment: HRMY scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $46.10 (+20.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HRMY is in a strong uptrend. Immediate support is located at $36.80, while resistance sits at $40.15.
Market Sentiment: HRMY scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $46.10 (+20.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$34.78 -
$38.47
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
53.8%
Protect Your Profits
Holding HRMY? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 20.9% below Wall St target ($46.10)
- WARNING: Composite score 44/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$34.78 -
$38.47
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
Âą$3.36
(8.8%)
Support & Resistance Levels
Support Level
$36.80
Resistance Level
$40.15
Current Trend
Strong Uptrend
Technical data as of
Aug 17, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.70
Wall Street Target
$46.10
(+20.9%)
Revenue Growth (YoY)
30.3%
Earnings Growth (YoY)
88.2%
Profit Margin
18.9%
Valuation Discount vs History
-1.1% cheaper
PE vs Historical
5.7 vs 5.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.1%
(market-implied from PE analysis)
1-Year Target
$37.72
(-1%)
2-Year Target
$37.31
(-2%)
3-Year Target
$36.90
(-3%)
3-Yr Target (if PE normalizes)
(PE: 6â6)
$38.16
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 28.1%)
$282.32
(+640%)
Base:
(SPY PE: 5.7, Growth: 28.1%)
$80.08
(+110%)
Bear:
(PE: 4.8, Growth: 28.1%)
$68.07
(+79%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (12x PE), but valuation improves significantly next year (6x PE) as earnings recover.
Trailing PE: 12.34 | Current EPS (TTM): $3.09
Bull Case
$83.86
(+120%)
Analyst growth 100.0%, PE expands to 13.6
Base Case
$76.24
(+100%)
Market implied 100.0%, PE stable at 12.3
Bear Case
$25.92
(-32%)
Severe decline -20.0%, PE contracts to 10.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.7 to 5.9
Stabilization Target:
$39.45
(+3.4%)
PE Expansion Potential:
+3.4%
Share & Embed Analysis
Last updated: August 17, 2026 8:14 PM ET
Data refreshes hourly during market hours. Next update: 9:14 PM
Data refreshes hourly during market hours. Next update: 9:14 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HRMY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 57 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 54 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 54 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 55 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
Advanced HRMY Option Strategies
Professional options setups generated by AI based on today's HRMY price and gamma walls.
